Sign in

NCT07855458Not yet recruiting

ESA Hyporesponsiveness in Hemodialysis Patients

Predictors of Development and Persistence of Erythropoietin-Stimulating Agents Hyporesponsiveness in Hemodialysis Patients

Source: ClinicalTrials.gov · Last updated 2 Oct 2026

Brief summary (registry, in English)

This prospective cohort study aims to evaluate the development, persistence, and recovery of erythropoiesis-stimulating agent (ESA) hyporesponsiveness among patients receiving maintenance hemodialysis.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
200 (estimated)
First submitted
28 Sept 2026
Start date
2 Oct 2026
Primary completion date
1 Oct 2027
Lead sponsor
Assiut University
NCT number
NCT07855458

What you commit to

  • Study type: Observational
  • Planned participants: 200
  • From 2 Oct 2026 to the primary completion date, 1 Oct 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Recent blood transfusion, e.g. within 3 months before enrollment.
  • Recent major surgery.
  • Recent kidney transplantation.

Other illness

  • Active malignancy.
  • Hematological malignancy.
  • Active major bleeding.

Lab values

  • Incomplete clinical or laboratory follow-up

Other

  • Known hemoglobinopathy causing anemia.
  • Pregnancy.
  • Known pure red-cell aplasia.

Who the study is looking for

  • Age ≥18 years.
  • ESRD/CKD G5D receiving maintenance hemodialysis.
  • Hemodialysis ≥3 months before enrollment.
  • Receiving ESA therapy for anemia.
  • Expected to remain on hemodialysis during the study period.
  • Baseline Hb and ESA dose available.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.